Skip to main navigation Skip to search Skip to main content

Choice of growth standard and interpretation of large for gestational age outcomes: evidence from the CDC4G trial

  • Sara Grass
  • , Maryam de Brun
  • , Anders Magnuson
  • , Martina Persson
  • , Anna Karin Wikström
  • , David Simmons
  • , Snehal Patil
  • , Verena Sengpiel
  • , Scott Montgomery
  • , Kerstin Berntorp
  • , Ulla Britt Wennerholm
  • , Helena Strevens
  • , Karin Hildén
  • , Elisabeth Storck-Lindholm
  • , Helena Backman
  • , Fredrik Ahlsson
  • Uppsala University
  • Karolinska Institutet
  • Örebro University
  • Sachsska Childrenśand Youth Hospital
  • University of Gothenburg
  • Sahlgrenska University Hospital
  • University College London
  • Lund University

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The lack of a standardised definition of large for gestational age (LGA) complicates clinical assessments and the interpretation of research. Objective: The objective of this study is to assess how different definitions of LGA affect the interpretation of outcomes in a stepped wedge cluster randomised controlled trial (SW-CRT). Methods: Secondary analysis of the Changing Diagnostic Criteria for Gestational Diabetes (CDC4G, ISRCTN41918550) study population (n = 47,080 pregnancies), including eight delivery units in Sweden during 2018. The outcome measures were the prevalence of LGA and severe LGA before and after switching from the previous Swedish diagnostic criteria for gestational diabetes (SWE-GDM) to the World Health Organisation (WHO-2013) criteria. LGA and severe LGA were defined as birthweight > 90th and > 97th percentile, respectively, using the following reference growth charts: The new Swedish reference ranges for foetal weight (SWE-REF), the Gestation Related Optimal Weight (GROW) and the International Foetal and Newborn Growth Consortium for the 21st Century (Intergrowth-21st). Analyses were performed on a modified intention-to-treat (mITT) population and on the subgroup discordant for GDM diagnosis between new and former criteria, i.e., glucose levels between the WHO-2013 and SWE-GDM diagnostic thresholds. Results: In the mITT population, the prevalence of LGA decreased from 19.4% to 13.1% after the switch to the WHO-2013 GDM criteria, as defined by SWE-REF (adjusted relative risk [RR], 0.92; 95% confidence interval [CI] 0.86, 0.98). There was no change in severe LGA using any of the reference charts. In the subgroup, LGA defined by SWE-REF (RR 0.68, 95% CI 0.50, 0.91) and GROW (RR 0.78, 95% CI 0.63, 0.95) was reduced, but not when defined by Intergrowth-21st (RR 0.88, 95% CI 0.74, 1.06). Severe LGA was reduced only when defined by Intergrowth-21st (RR 0.73, 95% CI 0.62, 0.85). Conclusions: The choice of LGA definition affected the interpretation of the results in the CDC4G trial.

Original languageEnglish
Number of pages9
JournalPaediatric and Perinatal Epidemiology
DOIs
Publication statusE-pub ahead of print (In Press) - 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • gestational diabetes mellitus
  • growth charts
  • large for gestational age

Fingerprint

Dive into the research topics of 'Choice of growth standard and interpretation of large for gestational age outcomes: evidence from the CDC4G trial'. Together they form a unique fingerprint.

Cite this